CDK6 protein expression has been recently demonstrated to indirectly predict for sensitivity to CDK4/6 inhibition in ER+ breast cancers, non-small cell lung carcinomas, colorectal carcinomas, and superficial spreading melanomas [13]. This evidence concerns the gene CDK4 and colorectal carcinoma.